Opioid treatment agreement and monitoring: what to expect at a pain clinic

Opioid treatment agreements and monitoring: what they are and why clinics use them for safety-first pain care [2026-09-05]

If you are considering or already using prescription opioids for ongoing pain, you may be asked to review an opioid treatment agreement and to participate in routine monitoring such as Prescription Drug Monitoring Program (PDMP) checks and urine drug screening. In safety-focused pain clinics, these steps are part of informed consent, shared expectations, and risk mitigation to support function and reduce the chance of medication-related harm [1]. Opioids are not the only option for chronic pain, and clinicians discuss nonopioid and nonpharmacologic therapies along with any potential role for opioids, weighing benefits and risks for the individual [1].

What an opioid treatment agreement is—and what it tries to accomplish

An opioid treatment agreement is a written summary of the goals, potential benefits and risks, and the responsibilities that both patient and clinician agree to consider when opioids are part of a care plan for chronic pain. It documents informed consent, clarifies how monitoring will occur, and outlines how decisions will be revisited over time to keep care as safety-focused and individualized as possible [1].

A discussion of expected benefits and known risks of opioids, including short- and long-term safety considerations, alongside nonopioid options and functional goals that matter to you [1].
How and when the plan will be reassessed, including the possibility of changing the dose, continuing, or tapering if the balance of benefits and risks changes; these are clinician-guided decisions made collaboratively, and individuals should not make medication changes without the prescribing clinician [1].
Which monitoring steps the clinic uses (for example, PDMP checks and urine or other toxicology testing), why they are used, and how results will be discussed in a supportive, nonpunitive manner focused on safety [1].
Policies that promote safe use, such as secure storage, not sharing medications, and discussing other medicines or substances that can increase risk, like benzodiazepines or alcohol [1].
Overdose risk education and when clinicians may offer naloxone to reduce overdose risk, especially if certain risk factors are present; naloxone decisions are individualized and clinician-led [1].

Monitoring during long-term opioid therapy: what to expect in a safety-first clinic

Monitoring is meant to support trust, transparency, and safety. Clinicians typically review pain and function, screen for side effects and risks, check the PDMP, and may use toxicology testing to assess for prescribed and nonprescribed substances that could affect safety. These steps are intended to inform shared decisions and reduce the chance of unintentional harms. The Centers for Disease Control and Prevention (CDC) recommends considering these tools before initiation and periodically during ongoing therapy [1].

PDMP checks: how they fit into opioid risk mitigation

A PDMP is a state-supported database that compiles dispensing information for controlled medications. Clinicians use PDMP checks to verify that the current plan aligns with recent dispensing, to identify potentially unsafe combinations such as concurrent opioid and benzodiazepine prescriptions, and to prompt timely conversations if entries are unclear or unexpected. The CDC recommends reviewing the PDMP before starting opioids and periodically during therapy as part of a comprehensive safety review [1].

Whether dispensing history aligns with the current care plan, so the clinician can address discrepancies together with you [1].
Potentially risky patterns or combinations (for example, overlapping controlled medications such as benzodiazepines) that may increase overdose risk and warrant discussion about safer approaches [1].

Urine drug screening in a pain clinic: purpose and process

Clinicians may use urine drug screening (toxicology testing) to inform safety—confirming the presence of prescribed medications and detecting nonprescribed or illicit substances that could increase risk. The CDC advises considering toxicology testing when opioids are used for chronic pain and discussing the rationale with patients in a way that is respectful and focused on safety, not punishment or dismissal [1].

Presumptive testing (often immunoassay-based) can provide rapid, initial results but may yield false positives or false negatives; results sometimes require confirmation [2].
Definitive testing (for example, mass spectrometry) identifies specific substances with greater accuracy and is typically used to confirm unexpected screening results or when more precise identification is medically necessary [2].
Testing is ordered when medically necessary to guide clinical decisions. Coverage policies emphasize that frequency and the choice between presumptive and definitive tests should be based on individual risk and clinical context, documented in the record [2].
Test results have limits: they can detect presence of a substance but do not measure the opioid dose taken, and some medications in the same class can be hard to distinguish on screening assays; clinicians interpret results cautiously and in conversation with the patient [1, 2].

Other opioid risk‑mitigation strategies you may hear about

Avoiding the routine combination of opioids with benzodiazepines or other sedatives when possible because this increases overdose risk; clinicians weigh benefits and risks if such combinations are considered [1].
Offering naloxone when risk factors for overdose are present, educating on its purpose and use, and discussing how household members could access it; this is a clinical decision tailored to individual risk [1].
Regular follow-up focused on function, side effects, and evolving risks, with careful consideration before any dose changes; abrupt discontinuation or rapid tapering can carry risks and should be avoided unless there is a life-threatening issue. Any tapering conversation should be collaborative and clinician-guided; individuals should not make medication changes without the prescribing clinician [1].

How agreements and monitoring support function, safety, and trust

A well-explained opioid treatment agreement and thoughtful monitoring can make expectations clear, reduce misunderstandings, and center the visit on practical goals like improved function, daily activity, and participation in rehabilitation. The CDC encourages clinicians to set functional goals, weigh benefits and risks at each step, and use tools such as PDMP review, toxicology testing, and overdose education to reduce preventable harms while supporting individualized pain care [1].

Visit questions that can align expectations for supervised opioid care

Bringing clear questions to your appointment can help the conversation stay focused on safety, function, and shared decision-making. Consider asking the following and taking notes on how the answers relate to your day-to-day function and rehabilitation goals.

What functional goals are we aiming for with this plan, and how will we know if opioids are helping me move toward them alongside nonopioid strategies [1]?
How does this clinic structure opioid treatment agreements—what do they include, and how often are we expected to revisit them as my situation changes [1]?
When and why do you check the PDMP, and how will you discuss any entries with me before making decisions [1]?
What is your approach to urine drug screening—what tests are used, how are results interpreted, and when is confirmatory testing considered medically necessary [1, 2]?
Under what circumstances would you consider offering naloxone, and what should I understand about its role in reducing overdose risk [1]?
If benefits and risks change over time, how would you approach any consideration of an opioid taper, and what supports would be in place to do this safely and gradually if needed; I will not change medications without the prescribing clinician [1]?
How do you approach potentially risky combinations, such as opioids with benzodiazepines or other sedatives, and what alternatives might be considered if relevant to my care [1]?

Respectful communication, limitations, and uncertainties to keep in view

Even when used carefully, monitoring tools have limits. PDMP data do not capture clinical context, and an entry may reflect care transitions or pharmacy processing rather than misuse; clinicians are encouraged to discuss PDMP findings with patients to avoid misinterpretation and to support safety-focused decisions [1]. Urine drug screening can miss some substances or show unexpected positives because of cross-reactivity; definitive testing may be needed to clarify results. Tests identify the presence of substances, not the dose taken, and results should be interpreted cautiously and discussed in a nonjudgmental way that keeps people engaged in care [1, 2]. When questions arise about continuing, adjusting, or tapering opioids, the CDC advises against abrupt discontinuation and emphasizes collaborative, individualized plans; do not make medication changes without the prescribing clinician [1].

Preparing for a conversation at CMS Pain Management & Rehab

CMS Pain Management & Rehab provides interdisciplinary pain and rehabilitation care. When opioids are considered, the team’s focus is on safety, function, and alignment with current guidance on informed consent, monitoring, and risk mitigation [3, 1]. Before a visit, it can help to collect a list of current medications, note any side effects or concerns, and think about functional goals that matter to you (for example, walking a certain distance or resuming specific daily activities). Questions in this guide can support a collaborative discussion; medication decisions remain clinician-led, and individuals should not change any prescriptions without talking to the prescribing clinician [1].

FAQs

Why do pain clinics use an opioid treatment agreement?

Clinicians use opioid treatment agreements to document informed consent, set functional goals, explain monitoring steps like PDMP checks and urine drug screening, and outline safety practices such as discussing risky combinations and considering naloxone when appropriate. They are intended to support shared decision-making and reduce preventable harms in long-term opioid therapy [1].

How often will my clinician check the PDMP, and what are they looking for?

The CDC recommends reviewing the PDMP before starting opioids and periodically during therapy to identify potentially unsafe patterns, such as overlapping controlled medications, and to prompt timely discussion. Frequency is influenced by state requirements and clinical judgment; your clinician can explain the schedule used in your situation [1].

Why is urine drug screening part of chronic pain care if I take my medicine as directed?

The CDC advises considering toxicology testing to inform safety when opioids are part of chronic pain care. Screening can verify the presence of prescribed medications and detect substances that could increase risk. Results are best used to guide conversation and safety planning, not to dismiss patients from care [1].

What happens if a urine drug screen shows something unexpected?

Screening immunoassays can produce false positives or negatives, and they do not measure how much medication was taken. When results are unexpected or more specificity is needed, definitive testing (for example, mass spectrometry) may be ordered if medically necessary. Clinicians interpret results cautiously and discuss them with patients to keep care focused on safety [2, 1].

What if my clinician brings up an opioid taper—what should I expect?

The CDC cautions that abrupt discontinuation or rapid tapering can cause harm and encourages collaborative, individualized plans when considering a change. If tapering is discussed, clinicians typically outline a gradual approach and supports; do not change medications without speaking with the prescribing clinician [1].

Sources

When to Talk With a Clinician

For non-emergency questions, contact CMS Pain Management & Rehab to discuss your symptoms and care options with a qualified clinician. For emergency warning signs, call 911 or seek emergency care now rather than contacting the clinic.

Medical disclaimer: This article is for general education and is not a diagnosis or a substitute for individualized medical advice. Treatment options, risks, and eligibility vary; consult a qualified healthcare professional.

Opioid treatment agreements and monitoring: what to expect at a pain clinic